RECORD // Company

Achieve Life Sciences, Inc.

Formerly: ONCOGENEX PHARMACEUTICALS, INC.; SONUS PHARMACEUTICALS INC

Built 2026-11-22T03:19:19Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (5)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Achieve Life Sciences, Inc. · Ct business · same registered legal name as 'ACHIEVE LIFE SCIENCES, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Achieve Life Sciences · Ctgov · exact name match to 'ACHIEVE LIFE SCIENCES, INC.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • Achieve Life Sciences, Inc. · East licences · same registered legal name as 'ACHIEVE LIFE SCIENCES, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ACHIEVE LIFE SCIENCES, INC. · Ny corps · same registered legal name as 'ACHIEVE LIFE SCIENCES, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ACHIEVE LIFE SCIENCES, INC. · USAspending · same registered legal name as 'ACHIEVE LIFE SCIENCES, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001193125-26-455463

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-12,110,0003 months ended 2026-09-3010-Q2026-11-100001193125-26-4554632026-11-22 03:19 UTCReport an error
Interest expense$258,0003 months ended 2026-09-3010-Q2026-11-100001193125-26-4554632026-11-22 03:19 UTCReport an error
Cash and cash equivalents$59,736,000at 2026-09-3010-Q2026-11-100001193125-26-4554632026-11-22 03:19 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000949858
Ticker
QUIT
EIN
954343413
CUSIP
004468500
Record ID
sx:sec:0000949858

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

31 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 03:19 UTCReport an error
SIC industry2835 In Vitro & In Vivo Diagnostic Substances2026-11-16SEC EDGAR company profile2026-11-22 03:19 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 03:19 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 03:19 UTCReport an error
Business address22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 980212026-11-16SEC EDGAR company profile2026-11-22 03:19 UTCReport an error
ExchangesNasdaq, Nasdaq2026-11-16SEC EDGAR company profile2026-11-22 03:19 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-54,648,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 03:19 UTCReport an error
Total assets (at 2025-12-31)$41,790,0002025-12-3110-K, XBRL Assets2026-11-22 03:19 UTCReport an error
Stockholders' equity (at 2025-12-31)$21,518,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 03:19 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$20,929,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 03:19 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-49,465,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 03:19 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$3,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 03:19 UTCReport an error
Form D total offering amount (D/A filed 2022-12-08)$25,000,0002022-12-08D/A2026-11-22 03:19 UTCReport an error
Form D total amount sold (D/A filed 2022-12-08)$18,900,0002022-12-08D/A2026-11-22 03:19 UTCReport an error
Form D industry groupBiotechnology2022-12-08D/A2026-11-22 03:19 UTCReport an error
Form D revenue rangeDecline to Disclose2022-12-08D/A2026-11-22 03:19 UTCReport an error
Form D date of first sale2022-11-182022-12-08D/A2026-11-22 03:19 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-10)On November 10, 2026, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.2026-11-10SEC EDGAR 8-K 0001193125-26-455404 (text as filed, excerpt)2026-11-22 03:19 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-14)On August 14, 2026, Achieve Life Sciences, Inc. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $150.0 million (the “ATM Shares”), through Jefferies, as sales agent, pursuant to an at-the-market offering program (the “ATM Program”). The ATM Shares offered and sold under the ATM Program will be issued pursuant to the Company’s Registration Statement on Form S-3 filed with the U.S. Securities and Exchange Commission on…2026-08-14SEC EDGAR 8-K 0001193125-26-352229 (text as filed, excerpt)2026-11-22 03:19 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-11)On August 11, 2026, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.2026-08-11SEC EDGAR 8-K 0001193125-26-344571 (text as filed, excerpt)2026-11-22 03:19 UTCReport an error
Plan (pension, plan no. 001)ACHIEVE LIFE SCIENCES INC. 401(K) RETIREMENT SAVINGS PLAN & TRUST: 34 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 03:19 UTCReport an error
Largest institutional holder #1 (13F as filed): Frazier Life Sciences Management, L.P.$49,724,8792026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #2 (13F as filed): TPG GP A, LLC$44,910,5972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #3 (13F as filed): venBio Partners LLC$38,623,1222026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #4 (13F as filed): Logos Global Management LP$35,425,2502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$34,426,2712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #6 (13F as filed): FRANKLIN RESOURCES INC$32,344,5272026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #7 (13F as filed): Paradigm Biocapital Advisors LP$32,335,6202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$27,039,5022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #9 (13F as filed): Propel Bio Management, LLC$26,342,1382026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error
Largest institutional holder #10 (13F as filed): MARSHALL WACE, LLP$24,620,1452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:19 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.